Skip to Content

Media Release

Basel, 15 April 2005

Roche clinical trial registry and results database launched on www.roche-trials.com

High degree of transparency to enhance communication between Roche, patients and doctors

Within only three months after deciding to create an electronic database, Roche is launching a public clinical trial registry and results database using an independent host, CenterWatch. On www.roche-trials.com information on Roche’s clinical trials can be accessed by anyone, anywhere, with no password restrictions. This site is designed to give patients and healthcare providers ready access to information they need, in terms they can understand.

Ed Holdener, Head of Global Pharma Development at Roche, said: “We are proud to go live with our publicly accessible protocol registry and clinical trial results database today. Transparency has always been and continues to be a priority for us. In January, we announced our plans to have an independent host for the database and since then, we selected CenterWatch, a company with a wealth of experience in the area of data management and the publication of clinical trial information. So for the first time ever, there is now a global and publicly accessible database, containing comprehensive information about Roche’s clinical trials”.

Roche expects that the huge task of publishing data from more than 30 medicines, on a product by product level from a large number of global and local trials, will take approximately a year. Roche will also continue to contribute information to established databases (i.e. www.clinicaltrials.gov)

Information that can be found in the electronic database
Starting with Fuzeon and Bondronat, clinical trial information will be added in a staged approach on the databases and will ultimately include protocol information and results from all Phase II to Phase IV clinical trials completed after 1 October, 2004. In addition, data from all Phase II to Phase IV clinical trials for medicines first marketed after 1 October, 2002 will be included retrospectively. The clinical trial registry and results database will also include interventional clinical studies from Roche Diagnostics.

Roche approach and possible industry solution
Roche is taking a leadership role in the industry’s efforts to ensure transparency with its global approach, which is consistent with the information disclosure principles published earlier this year by the European Federation of Pharmaceutical Industry Associations (EFPIA).
The Roche strategy may model an industry-wide solution. Roche would support and participate in a future industry solution that provides a public database in which all companies can publish both national and international protocol information and trial results. Roche would be delighted if this independent solution would lead other pharmaceutical companies to use the CenterWatch repository to register ongoing clinical trials and report results of trials.
CenterWatch is a leader in web design and experienced in the implementation of websites for clinical trial listings and clinical trial results, and already has an established reputation as an independent source that the public trusts for clinical trial listings and results. Having CenterWatch host Roche’s clinical trials databases provides the widest possible exposure, and makes it easy for the public to obtain important information in this area.

Strict adherence to regulations of clinical trials
Roche works to ensure that all its activities are performed in accordance with ethical and regulatory requirements. Moreover, Roche is strongly committed to verifying adherence to compliance policies. Adequate and ongoing peer review is a key prerequisite for maintaining high ethical standards in Roche’s clinical trials and development activities.
In addition, Roche adheres to the “Declaration of Helsinki”, a statement developed by the World Medical Association on ethical principles to provide guidance to physicians and other participants in medical research involving human subjects. Roche also strictly follows the rules of good clinical practice (GCP), which ensure the protection of patients’ safety and rights.

About CenterWatch
Thomson CenterWatch (CW) is part of Thomson Healthcare and Scientific, probably best known as publishers of the PDR (Physician's Desk Reference) and Current Drugs. Thomson Healthcare and Scientific is a division of the Thomson Corporation, a Canadian based information services provider. For over a decade, CW has been the leading provider of clinical trials information to healthcare professionals and the patient community. Their market intelligence data and editorial content is highly respected among global pharmaceutical industry professionals. They publish eight top-selling guidebooks covering training issues for today’s clinical research professionals. In 1995 CW launched the www.centerwatch.com web site and began publishing listings of clinical trials seeking patient volunteers. The oldest and largest trial database on the web, the Clinical Trials Listing Service™ now lists nearly 15,000 industry-sponsored clinical trials, as well as an additional 20,000 clinical trials sponsored by the NIH and NCI. In 2004 alone, nearly 10 million people will visit the site directly or access information through their vast network of content partners.

About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2004 sales by the Pharmaceuticals Division totalled 21.7 billion Swiss francs, while the Diagnostics Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 65,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet (www.roche.com).

All trademarks used or mentioned in this release are legally protected.



Further information:
- Roche and clinical trials: www.roche.com/sus_res_clin
- Clinical trials: www.roche.com/sci_events_facets_clinical
- EFPIA position statement: www.efpia.org/4_pos/sci_regu/Clinicaltrials2005.pdf
- Declaration of Helsinki: www.wma.net/e/policy/b3.htm